Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease

Parkinson's Disease

Volumn 1, Issue , 2015, Pages

  De Jesús Cortés, Héctor ^a,b   Miller, Adam D ^b   Britt, Jeremiah K ^b   DeMarco, Anthony J ^b   De Jesús Cortés, Mayralis ^b   Stuebing, Emily ^b   Naidoo, Jacinth ^c   Vázquez Rosa, Edwin ^b   Morlock, Lorraine ^c   Williams, Noelle S ^c   Ready, Joseph M ^c   Narayanan, Nandakumar S ^b   Pieper, Andrew A ^b,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; P7C3 A20; P7C3 S243; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL SURVIVAL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; CYLINDER TEST; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; EXPOSURE; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; RAT; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84978993731     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1038/npjparkd.2015.10     Document Type: Review

References (23)

1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
2. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142: 39-51.
3. MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L et al. Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc 2011; 133: 1428-1437.
4. Pieper AA, McKnight SL, Ready JM. P7C3 and an unbiased approach to drug discovery for neurodegenerative disease. Chem Soc Rev 2014; 43: 6716-6726.
5. Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014; 158: 1324-1334.
6. Asai-Coakwell M, March L, Dai XH, Duval M, Lopez I, French CR et al. Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophies. Hum Mol Genet 2013; 22: 1432-1442.
7. Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2012; 109: 17016-17021.
8. Kemp SW, Szynkaruk M, Stanoulis KN, Wood MD, Liu EH, Willand MP et al. Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury. Neuroscience 2015; 284: 202-216.
9. Walker AK, Rivera PD, Wang Q, Chuang JC, Tran S, Osborne-Lawrence S et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry 2015; 20: 500-508.
10. Blaya MO, Bramlett HM, Naidoo J, Pieper AA, Dietrich WD. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma 2014; 31: 476-486.
11. Yin TC, Britt JK, De Jesús-Cortés H, Lu Y, Genova RM, Khan MZ et al. P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep 2014; 8: 1731-1740.
12. Dutca LM, Stasheff SF, Heberg-Buenz A, Rudd D, Batra N, Blodi FR et al. Early and noninvasive detection of subclinical visual damage after blast-mediated traumatic brain injury enables prevention of chronic visual deficit by treatment with P7C3- S243. Invest Ophthalmol Vis Sci 2014; 55: 8330-8341.
13. Cain C. NAMPT neuroprotection. SciBX 2014; 7: 1-2.
14. De Jesús-Cortés H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S et al. Neuroprotective efficacy of aminopropyl carabzoles in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 2012; 109: 17010-17015.
15. Naidoo J, De Jesus-Cortes H, Huntington P, Estill S, Morlock LK, Starwalt R et al. Discovery of a neuroprotective chemical, (S)-N-(3-(3, 6-dibromo-9H-carbazol-9-yl)- 2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties. J Med Chem 2014; 57: 3746-3754.
16. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Re 2004; 318: 215-224.
17. Sarre S, Yuan H, Jonker N, Ven Hemelrijck A, Ebinger G, Michotte Y. In vivo characterization of somatodendritic release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 2004; 90: 29-39.
18. Tétrault S, Chever O, Sik A, Amzica F. Opening of the blood-brain barrier during isoflurane anaesthesia. Eur J Neurosci 2008; 28: 1330-1341.
19. Dittmar MS, Petermichl W, Schlachetzki F, Graf BM, Gruber M. Isoflurane induces endothelial apoptosis of the post-hypoxic blood-brain barrier in a transdifferentiated human umbilical vein endothelial cell model. PLoS One 2012; 7: e38260.
20. Cao Y, Ni C, Li Z, Li L, Liu Y, Wang C et al. Isoflurane anesthesia results in reversible ultrastructure and occludin tight junction protein expression changes in hippocampal blood-brain barrier in aged rats. Neurosci Lett 2015; 587: 51-56.
21. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-787.
22. Robinson TE, Noordhoom M, Chan EM, Mocsary Z, Camp DM, Whishaw IQ. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6- OHDA lesion of the substantia nigra. Synapse 1994; 17: 16-25.
23. Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D et al. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther 2008; 16: 1392-1399.